UY37448A - Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus - Google Patents

Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus

Info

Publication number
UY37448A
UY37448A UY0001037448A UY37448A UY37448A UY 37448 A UY37448 A UY 37448A UY 0001037448 A UY0001037448 A UY 0001037448A UY 37448 A UY37448 A UY 37448A UY 37448 A UY37448 A UY 37448A
Authority
UY
Uruguay
Prior art keywords
polypeptide
staphylococcus
infections caused
against infections
vaccine constructs
Prior art date
Application number
UY0001037448A
Other languages
English (en)
Inventor
Malouin François
Ster Céline
Côté-Gravel Julie
Brouillette Éric
Original Assignee
Socpra Sciences Et Genie Sec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Socpra Sciences Et Genie Sec filed Critical Socpra Sciences Et Genie Sec
Publication of UY37448A publication Critical patent/UY37448A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un constructo de fusión X-A-ligante-B-Zdonde A y B son: (a) un polipéptido del genoma COL (SACOL) de Staphylococcus aureus de la Secuencia de Referencia de NCBI NC_002951.2; (b) un polipéptido codificado por un gen de un mismo operón que codifica al polipéptido de (a); (c) un polipéptido con un fragmento inmunogénico de (a) o (b); (d) un polipéptido con una secuencia de aminoácidos 60% idéntica a la secuencia del polipéptido de (a) a (c); (e) un polipéptido con una variante inmunogénica de (a) a (c); el ligante, X, Y, o Z es una secuencia de aminoácidos o está ausente
UY0001037448A 2016-10-21 2017-10-20 Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus UY37448A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662411120P 2016-10-21 2016-10-21

Publications (1)

Publication Number Publication Date
UY37448A true UY37448A (es) 2018-03-23

Family

ID=62018642

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037448A UY37448A (es) 2016-10-21 2017-10-20 Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus

Country Status (24)

Country Link
US (2) US11324815B2 (es)
EP (1) EP3529260A4 (es)
JP (2) JP7181208B2 (es)
KR (1) KR20190082229A (es)
CN (1) CN109843910A (es)
AR (1) AR109847A1 (es)
AU (2) AU2017346974B2 (es)
BR (1) BR112019007796A2 (es)
CA (1) CA3037070A1 (es)
CL (1) CL2019001048A1 (es)
CO (1) CO2019005169A2 (es)
CR (1) CR20190249A (es)
DO (1) DOP2019000102A (es)
IL (1) IL265869A (es)
MX (2) MX2019004539A (es)
MY (1) MY195369A (es)
NZ (1) NZ751880A (es)
PE (1) PE20191320A1 (es)
PH (1) PH12019500843A1 (es)
RU (2) RU2022100889A (es)
SG (2) SG11201901483QA (es)
TW (1) TW201819402A (es)
UY (1) UY37448A (es)
WO (1) WO2018072031A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022125928A1 (en) * 2020-12-11 2022-06-16 Bayer Animal Health Gmbh Methods and compositions for improved production of an antigen for use in an s. aureus vaccine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0187702B1 (en) 1985-01-07 1990-03-14 Syntex (U.S.A.) Inc. N-(omega,omega-1-dialkoxy)- and n-(omega,omega-1-dialkenoxy)-alk-1-yl-n,n,n-trisubstituted ammonium surfactants, their preparation and pharmaceutical formulations containing them
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US7060458B1 (en) 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6380370B1 (en) 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6833134B2 (en) 2000-06-12 2004-12-21 University Of Saskacthewan Immunization of dairy cattle with GapC protein against Streptococcus infection
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
EP1565478B1 (en) 2002-11-12 2017-08-02 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
CN1569893A (zh) 2003-07-21 2005-01-26 中国人民解放军军事医学科学院基础医学研究所 金葡菌毒力因子调控蛋白的抗原表位及其模拟表位和用途
RU2419628C2 (ru) 2004-09-22 2011-05-27 ГлаксоСмитКлайн Байолоджикалз с.а. Иммуногенная композиция для применения в вакцинации против стафилококков
US8445000B2 (en) * 2004-10-21 2013-05-21 Wyeth Llc Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens
KR100729954B1 (ko) 2004-12-01 2007-06-20 주식회사 엘지생명과학 Ｓｅｃ１ 변이 단백질의 제형 및 그것의 제형화 방법
WO2008152447A2 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
US9932373B2 (en) 2009-03-23 2018-04-03 Epitopix, Llc Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
US8679505B2 (en) 2009-04-14 2014-03-25 Novartis Ag Compositions for immunising against Staphylococcus aureus
CA2792956C (en) 2010-03-17 2021-11-16 Socpra - Sciences Et Genie, S.E.C. Bacterial vaccine components from staphylococcus aureus and uses thereof
US9091689B2 (en) 2011-06-19 2015-07-28 New York University Methods of treating and preventing staphylococcus aureus infections and associated conditions

Also Published As

Publication number Publication date
AU2022204585A1 (en) 2022-07-21
CA3037070A1 (en) 2018-04-26
AU2017346974A1 (en) 2019-03-14
RU2019115303A3 (es) 2021-03-02
JP2019531100A (ja) 2019-10-31
AU2017346974B2 (en) 2022-03-31
RU2019115303A (ru) 2020-11-23
US20190216913A1 (en) 2019-07-18
BR112019007796A2 (pt) 2019-09-03
RU2022100889A (ru) 2022-04-06
CL2019001048A1 (es) 2019-08-30
AR109847A1 (es) 2019-01-30
EP3529260A4 (en) 2020-12-16
PH12019500843A1 (en) 2019-12-02
MX2023001219A (es) 2023-03-03
KR20190082229A (ko) 2019-07-09
RU2766354C2 (ru) 2022-03-15
CO2019005169A2 (es) 2019-08-09
EP3529260A1 (en) 2019-08-28
SG10201912431XA (en) 2020-02-27
DOP2019000102A (es) 2019-07-15
US11324815B2 (en) 2022-05-10
CR20190249A (es) 2019-10-16
JP2023025066A (ja) 2023-02-21
IL265869A (en) 2019-06-30
MX2019004539A (es) 2019-06-12
JP7181208B2 (ja) 2022-11-30
MY195369A (en) 2023-01-16
PE20191320A1 (es) 2019-09-24
TW201819402A (zh) 2018-06-01
US20220288183A1 (en) 2022-09-15
SG11201901483QA (en) 2019-03-28
CN109843910A (zh) 2019-06-04
NZ751880A (en) 2023-04-28
WO2018072031A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
NI201800121A (es) Proteínas de fusión gdf15 y usos de estas
CL2018002825A1 (es) Vacuna contra vrs
BR112018007622A2 (pt) ferramenta genética de transformação de bactérias clostridium
PE20171382A1 (es) ARNi VARIANTE
CO2017006495A2 (es) Bacteriófago esc-cop-1 de e. coli tipo f18 productora de toxina shiga para inhibir la proliferación de e. coli tipo f18 productora de toxina shiga
AR105470A1 (es) Métodos para inducir una respuesta inmune
ES2722799T3 (es) Vacunas contra el cáncer de cerebro basadas en el péptido alfa 2 del receptor de interleuquina-13
UA115348C2 (uk) Композиція для попередження інфекції mycoplasma spp.
EA201692025A1 (ru) Доставка белков, осуществляемая на основе бактерий
BR112018077358A2 (pt) tagatose-6-fosfato fosfatase termoestável inovadora e um método para produzir tagatose com o uso da mesma
CO2018006947A2 (es) Novedoso bacteriófago pas-mup-1 de pasteurella multocida y su uso para inhibir la proliferación de pasteurella multocida
PE20220960A1 (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidopteros
CO2017006496A2 (es) Bacteriófago de e. coli enteroinvasiva esc-cop-4 para inhibir la proliferación de e. coli enteroinvasiva
BR112017020308A2 (pt) udp-glicosiltransferases
PE20170955A1 (es) Nuevas proteinas inhibidoras de insectos
CO2019010062A2 (es) Novedoso bacteriófago clo-pep-2 de clostridium perfringens y su uso para inhibir la proliferación de clostridium perfringens
CO6731074A2 (es) Composición vacunal para el control de las infestaciones por ectoparásitos
BR112016016103A2 (pt) Composição de antígenos micobacterianos
BR112018001121A2 (pt) vetor recombinante do vírus orf (orfv), célula, composição, uso de um vetor recombinante de orfv, e, molécula de ácido nucleico
CU20210061A7 (es) Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer
UY37448A (es) Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus
BR112017018966A2 (pt) gene de resistência a míldio em kalanchoe
UA114997C2 (uk) Рекомбінантний мікроорганізм з роду escherichia, що виробляє l-амінокислоту, та спосіб одержання l-амінокислоти
CO2018007442A2 (es) Vacunas contra el cáncer
BR112022010228A2 (pt) Vacinas de parasita de leishmania viva atenuada com características de segurança aumentadas